GLP-1 Market
LLY $1184.63 ▼ -0.0% NVO $38.31 ▼ -1.0% PFE $28.72 • 0.0% VKTX $31.81 ▼ -3.7% KLRA $10.99 ▼ -1.2% GPCR $32.69 ▼ -6.8% RHHBY $52.25 ▼ -2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Vibegron

Company
Wake Forest University Health Sciences
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Find a Clinical Trial Near Me

See recruiting studies for Vibegron and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05491525

    Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

    Not yet reported, Not yet reported Urovant Sciences GmbH 71 participants Est. completion 2030-09 38 sites Stand-alone
    Other conditions: Neurogenic Detrusor Overactivity
    View official trial listing →
  • Recruiting NCT NCT06417177

    Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

    Not yet reported University of Missouri-Columbia 75 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Aging, Menopause, Hypoxia, Vasodilation
    View official trial listing →
  • Recruiting NCT NCT07674680

    Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women

    Not yet reported University of Missouri-Columbia 60 participants Est. completion 2029-05 1 site Stand-alone
    Other conditions: Women, Aging, Menopause
    View official trial listing →
  • Completed NCT NCT01314872

    A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

    Not yet reported Merck Sharp & Dohme LLC 1395 participants Est. completion 2013-10-10 Stand-alone
    Other conditions: Urinary Bladder, Overactive
    View official trial listing →
  • Terminated NCT NCT01500382

    A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

    Not yet reported Merck Sharp & Dohme LLC 4 participants Est. completion 2013-01-02 Stand-alone
    Other conditions: Overactive Bladder, Overactive Urinary Bladder
    View official trial listing →
  • Completed NCT NCT01628042

    A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

    Not yet reported Merck Sharp & Dohme LLC 32 participants Est. completion 2013-01-25 Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT01737684

    A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

    Not yet reported Merck Sharp & Dohme LLC 16 participants Est. completion 2013-06-14 Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT03492281

    A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

    Not yet reported Urovant Sciences GmbH 1530 participants Est. completion 2019-02-04 215 sites Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT03583372

    An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

    Not yet reported Urovant Sciences GmbH 506 participants Est. completion 2019-07-25 107 sites Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT03806127

    Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

    Not yet reported Urovant Sciences GmbH 222 participants Est. completion 2020-10-06 41 sites Stand-alone
    Other conditions: Irritable Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT03902080

    Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

    Not yet reported Urovant Sciences GmbH 1105 participants Est. completion 2023-06-15 140 sites Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT04103450

    Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

    Not yet reported Urovant Sciences GmbH 276 participants Est. completion 2022-07-29 35 sites Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT04917315

    To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

    Not yet reported Jeil Pharmaceutical Co., Ltd. 210 participants Est. completion 2021-08-18 1 site Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT05067478

    Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

    Urovant Sciences GmbH 403 participants Est. completion 2024-07-26 64 sites
    Other conditions: Overactive Bladder
    View official trial listing →
  • Active, not recruiting NCT NCT05806164

    Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

    Not yet reported Women and Infants Hospital of Rhode Island 432 participants Est. completion 2030-08-01 5 sites
    Other conditions: Urgency Urinary Incontinence
    View official trial listing →
  • Withdrawn NCT NCT06438861

    Role of Combination Therapy in Women With Refractory Overactive Bladder

    Not yet reported University of Alabama at Birmingham Est. completion 2025-12-31
    Other conditions: Overactive Bladder Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT06987383

    Vibegron for ENergy Thinking and Resilience in Aging

    Not yet reported Wake Forest University Health Sciences 40 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07398261

    Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

    Not yet reported Menoufia University 151 participants Est. completion 2026-11-01 1 site
    Other conditions: Treatment of Non-monosymptomatic Nocturnal Enuresis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Vibegron, GEMTESA

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.